Dr Andrew Stone

Gee JMW; Stone A; McClelland RA; Hiscox S; Hutcheson IR; Jordan NJ; Fiegl HM; Widschwendter M; Shaw VE; Barrow D; Nicholson RI, 2009, 'The dark side of antihormonal action in breast cancer', in Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets, pp. 63 - 83, http://dx.doi.org/10.1007/978-1-4020-8526-0_4

Pinese M; Lacaze P; Rath EM; Stone A; Brion MJ; Ameur A; Nagpal S; Puttick C; Husson S; Degrave D; Cristina TN; Kahl VFS; Statham AL; Woods RL; McNeil JJ; Riaz M; Barr M; Nelson MR; Reid CM; Murray AM; Shah RC; Wolfe R; Atkins JR; Fitzsimmons C; Cairns HM; Green MJ; Carr VJ; Cowley MJ; Pickett HA; James PA; Powell JE; Kaplan W; Gibson G; Gyllensten U; Cairns MJ; McNamara M; Dinger ME; Thomas DM, 2020, 'The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly', Nature Communications, vol. 11, http://dx.doi.org/10.1038/s41467-019-14079-0

Lacaze P; Pinese M; Kaplan W; Stone A; Brion MJ; Woods RL; McNamara M; McNeil JJ; Dinger ME; Thomas DM, 2019, 'The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design', European Journal of Human Genetics, vol. 27, pp. 308 - 316, http://dx.doi.org/10.1038/s41431-018-0279-z

Milevskiy MJG; Gujral U; Del Lama Marques C; Stone A; Northwood K; Burke LJ; Gee JMW; Nephew K; Clark S; Brown MA, 2019, 'MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer', British Journal of Cancer, vol. 120, pp. 621 - 632, http://dx.doi.org/10.1038/s41416-019-0395-8

Humphris JL; Patch AM; Nones K; Bailey PJ; Johns AL; McKay S; Chang DK; Miller DK; Pajic M; Kassahn KS; Quinn MCJ; Bruxner TJC; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Stone A; Wilson PJ; Anderson M; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Waddell N; Wood S; Mead RS; Xu Q; Wu J; Pinese M; Cowley MJ; Jones MD; Nagrial AM; Chin VT; Chantrill LA; Mawson A; Chou A, 2017, 'Hypermutation In Pancreatic Cancer', Gastroenterology, vol. 152, pp. 68 - 74.e2, http://dx.doi.org/10.1053/j.gastro.2016.09.060

Locke WJ; Zotenko E; Stirzaker C; Robinson MD; Hinshelwood RA; Stone A; Reddel RR; Huschtscha LI; Clark SJ, 2015, 'Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis', Clinical Epigenetics, vol. 7, http://dx.doi.org/10.1186/s13148-015-0086-0

Stirzaker C; Zotenko E; Song JZ; Qu W; Nair SS; Locke WJ; Stone A; Armstong NJ; Robinson MD; Dobrovic A; Avery-Kiejda KA; Peters KM; French JD; Stein S; Korbie DJ; Trau M; Forbes JF; Scott RJ; Brown MA; Francis GD; Clark SJ, 2015, 'Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value', Nature Communications, vol. 6, pp. 5899 - 5899, http://dx.doi.org/10.1038/ncomms6899

Stone A; Zotenko E; Locke WJ; Korbie D; Millar EKA; Pidsley R; Stirzaker C; Graham P; Trau M; Musgrove EA; Nicholson RI; Gee JMW; Clark SJ, 2015, 'DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer', Nature Communications, vol. 6, http://dx.doi.org/10.1038/ncomms8758

Stone A; Musgrove EA, 2014, 'Endocrine therapy: Defining the path of least resistance', Breast Cancer Research, vol. 16, http://dx.doi.org/10.1186/bcr3659

Browne BC; Hochgräfe F; Wu J; Millar EKA; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JMW; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ, 2013, 'Global characterization of signalling networks associated with tamoxifen resistance in breast cancer', FEBS Journal, vol. 280, pp. 5237 - 5257, http://dx.doi.org/10.1111/febs.12441

Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JMW; Nicholson RI; Print CG; Clark SJ; Musgrove EA, 2013, 'BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer', Molecular Cancer Therapeutics, vol. 12, pp. 1874 - 1885, http://dx.doi.org/10.1158/1535-7163.MCT-13-0012

Stone A; Valdes-Mora F; Clark SJ, 2013, 'Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer', Epigenomics, vol. 5, pp. 595 - 598, http://dx.doi.org/10.2217/epi.13.70

Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA, 2012, 'Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells', MOLECULAR CANCER THERAPEUTICS, vol. 11, pp. 1488 - 1499, http://dx.doi.org/10.1158/1535-7163.MCT-11-0963

Caldon CE; Sergio CM; Kang JW; Muthukaruppan A; Boersma M; Stone A; Barraclough J; Lee CS; Black MJ; Miller LA; Gee JMW; Robert i nicholson RI; Sutherland RL; Print C; Musgrove EA, 2012, 'Cyclin E2 overexpression is associated with endocrine resistance but not insensivity to CDK2 inhibition in human breast cancer cells', Molecular Cancer Therapeutics, vol. 11, pp. 1488 - 1499, http://dx.doi.org/10.1158/1535-7163.MCT-11-0963

Kalyuga M; Gallego-Ortega D; Lee H; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Rosalind launchbury R; Statham A; Armstrong NJ; Alles MC; Adelaide young A; Egger A; Au W; Piggin CL; Evans C; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JMW; Robert i nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ, 2012, 'ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer', PLoS Biology, vol. 10, pp. e1001461, http://dx.doi.org/10.1371/journal.pbio.1001461

Stone A; Sutherland RL; Musgrove EA, 2012, 'Inhibitors of cell cycle kinases: Recent advances and future prospects as cancer therapeutics', Critical Reviews in Oncogenesis, vol. 17, pp. 175 - 198, http://dx.doi.org/10.1615/CritRevOncog.v17.i2.40

Stone A; Valdes-Mora F; Gee JM; Farrow L; Mcclelland RS; Fiegl H; Dutkowski C; McCloy RA; Sutherland RL; Musgrove EA; Robert i nicholson RI, 2012, 'Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer', PLoS One, vol. 7, pp. e40466, http://dx.doi.org/10.1371/journal.pone.0040466

Musgrove EA; Caldon CE; Barraclough J; Stone A; Sutherland RL, 2011, 'Cyclin D as a therapeutic target in cancer', Nature Reviews Cancer, vol. 11, pp. 558 - 572, http://dx.doi.org/10.1038/nrc3090

Stone A; Jones H; Giles M; Gee J; Nicholson R, 2008, 'Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity', Breast Cancer Research, vol. 10, http://dx.doi.org/10.1186/bcr1925

Stone A, 2003, 'FDA issues felled advanced tissue sciences', Genetic Engineering News, vol. 23

Milevskiy MJG; Gujral U; Lama Marques CD; Stone A; Northwood K; Burke LJ; Gee JMW; Nephew K; Clark S; Brown MA, 2018, MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ Breast Cancer, http://dx.doi.org/10.1101/329227

Milevskiy MJ; Al-Ejeh F; Saunus JM; Northwood KS; McCart-Reed AE; Dray E; Nephew K; Bailey PJ; Betts JA; Stone A; Gee JMW; Shewan AM; French JD; Edwards SL; Clark SJ; Lakhani SR; Brown MA, 2016, 'Abstract 1980: Long-range regulation of HOTAIR identifies novel biomarkers of breast cancer outcome and suggests a role in genome instability', in Cancer Research, American Association for Cancer Research (AACR), pp. 1980 - 1980, presented at Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA, http://dx.doi.org/10.1158/1538-7445.am2016-1980